ADVFN Logo
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover
Premium Connexion/S'inscrire Profile Icon
CAC 40
7 526,55
(
1,32%
)
Dow Jones
36 247,87
(
0,36%
)
DAX
16 759,22
(
0,78%
)
Brent Oil
75,965
(
0,0%
)
Bitcoin
43 811,55
(
0,21%
)
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. Actinium Pharmaceuticals Inc (ATNM)

  7. Actinium Pharmaceuticals Inc (ATNM) Actualités

ATNM Actinium Pharmaceuticals Inc

5,45
0,15 (2,83%)
09 Déc 2023 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Actinium Pharmaceuticals Inc ATNM AMEX Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,15 2,83% 5,45 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
5,35 5,19 5,44 5,32 5,30
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
08/12/202314:00PRNUSActinium to Highlight Broad Potential of Targeted..
01/12/202323:00EDGAR2Form 8-K - Current report
09/11/202323:09EDGAR2Form ARS - Annual Report to Security Holders
09/11/202323:05EDGAR2Form DEF 14A - Other definitive proxy statements
06/11/202313:30PRNUSActinium Presents Preclinical Data at SITC Demonstrating..
02/11/202321:15PRNUSActinium Pharmaceuticals to Attend Bio-Europe Munich 2023
02/11/202314:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202314:05PRNUSActinium Announces Oral Presentation at ASH Annual Meeting..
04/10/202313:30PRNUSActinium Announces NIH Grant Extension to Advance Clinical..
27/9/202315:05PRNUSActinium Pharma Highlights Abstract Accepted for Poster..
07/9/202314:40PRNUSActinium Pharma Presents Survival Data from Extended..
31/8/202313:00PRNUSActinium Pharma Highlights Three Abstracts Accepted for..
21/8/202313:00PRNUSActinium Pharma Highlights Abstracts Accepted for Oral and..
14/8/202323:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202315:00EDGAR2Form S-3 - Registration statement under Securities Act of..
24/7/202313:00PRNUSActinium Pharma to Present at the 2nd Annual Targeted..
26/6/202313:00PRNUSSNMMI 2023 Annual Meeting Abstract of the Year Awarded to..
23/6/202314:00PRNUSActinium Pharma Highlights Six Abstracts Accepted for Oral..
16/6/202313:00PRNUSActinium Pharma to Present at the Maxim Healthcare Virtual..
14/6/202313:00PRNUSActinium Pharma to Present at the TD Cowen..
12/6/202313:00PRNUSActinium Announces Positive Pivotal Phase 3 SIERRA Trial..
07/6/202313:00PRNUSActinium Pharma Set to Join Russell 2000® and Russell 3000®..
22/5/202313:00PRNUSActinium Pharma Announces Six Abstracts Accepted for Oral..
11/5/202317:18PRNUSActinium Pharma Announces Iomab-B SIERRA Trial Results..
10/5/202313:00PRNUSActinium Pharma to Present at Guggenheim Healthcare Talks..
28/4/202314:00PRNUSActinium Highlights Successful Administration of Targeted..
27/4/202316:36PRNUSActinium Announces Positive Pivotal Phase 3 SIERRA Trial..
12/12/202217:05TRMNJonesTrading Keeps Their Buy Rating on Actinium..

Dernières Valeurs Consultées

AMEX
ATNM
Actinium Pharmaceuticals
Delayed Upgrade Clock

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Support: support@advfn.fr